These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Statin therapy. Best RA Clin Med (Lond); 2001; 1(3):248. PubMed ID: 11446630 [No Abstract] [Full Text] [Related]
3. Optimal goals for statin use in patients with coronary artery disease. Ray KK; Cannon CP Curr Opin Cardiol; 2005 Nov; 20(6):525-9. PubMed ID: 16234625 [TBL] [Abstract][Full Text] [Related]
4. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Ray KK; Cannon CP Curr Opin Lipidol; 2004 Dec; 15(6):637-43. PubMed ID: 15529022 [TBL] [Abstract][Full Text] [Related]
5. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Rackley CE Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986 [TBL] [Abstract][Full Text] [Related]
6. Managing dyslipidemia in the high-risk patient. Stein EA Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720 [TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol. Sotiriou CG; Cheng JW Ann Pharmacother; 2000 Dec; 34(12):1432-9. PubMed ID: 11144702 [TBL] [Abstract][Full Text] [Related]
8. [Primary and secondary prevention of coronary disease by statins]. Ferrières J Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
10. A clinical focus on statins. Auer J; Eber B Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709 [TBL] [Abstract][Full Text] [Related]
11. [Atherosclerosis in light of the evidence from large statin trials]. Cortese C; Bernardini S; Motti C Ann Ital Med Int; 2000; 15(1):103-7. PubMed ID: 10842899 [TBL] [Abstract][Full Text] [Related]
12. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Rosenson RS; Tangney CC JAMA; 1998 May; 279(20):1643-50. PubMed ID: 9613915 [TBL] [Abstract][Full Text] [Related]
13. [Statins: similarities and differences in the pharmacological, clinical and laboratory aspects]. Motti C; Gnasso A; Cortese C Ann Ital Med Int; 2000; 15(1):96-102. PubMed ID: 10842898 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Boden WE Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126 [TBL] [Abstract][Full Text] [Related]
15. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. Frisinghelli A; Mafrici A Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568 [TBL] [Abstract][Full Text] [Related]
16. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Pedersen TR; Tobert JA Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485 [TBL] [Abstract][Full Text] [Related]
17. [Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes]. Hennekens C Am J Cardiovasc Drugs; 2007; 7 Spec No 1():9-11. PubMed ID: 19839182 [TBL] [Abstract][Full Text] [Related]